US · COLL
Collegium Pharmaceutical, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Stoughton, MA 02072
- Website
- collegiumpharma.com
Price · as of 2025-12-31
$34.32
Market cap 1.32B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $80.25 | +133.83% |
| Intrinsic Value(DCF) | $229.65 | +569.14% |
| Graham-Dodd Method(GD) | $14.83 | -56.8% |
| Graham Formula(GF) | $60.88 | +77.4% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $17.66 | ||||
| 2016 | $16.19 | ||||
| 2017 | $26.80 | $229.83 | $1.10 | $0.00 | $0.00 |
| 2018 | $18.07 | $243.85 | $1.37 | $0.00 | $0.00 |
| 2019 | $21.58 | $58.65 | $4,059.09 | $0.00 | $0.00 |
| 2020 | $25.44 | $61.71 | $188.84 | $9.29 | $9.59 |
| 2021 | $17.20 | $83.35 | $3.68 | $16.04 | $0.00 |
| 2022 | $24.39 | $45.38 | $852.19 | $0.00 | $0.00 |
| 2023 | $37.60 | $64.48 | $1,141.69 | $8.96 | $41.91 |
| 2024 | $28.91 | $81.98 | $915.46 | $12.78 | $40.81 |
| 2025 | $41.60 | $80.25 | $830.64 | $14.83 | $60.88 |
AI valuation
Our deep-learning model estimates Collegium Pharmaceutical, Inc.'s (COLL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $80.25
- Current price
- $34.32
- AI upside
- +133.83%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$229.65
+569.14% upside
Graham-Dodd
$14.83
-56.8% upside
Graham Formula
$60.88
+77.4% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| COLL | Collegium Pharmaceutical,… | $34.32 | 1.32B | +134% | +569% | -57% | +77% | 20.98 | 4.37 | 1.69 | 4.41 | — | -2.57 | 59.35% | 23.01% | 8.05% | 23.70% | 14.73% | 3.79% | 2.70 | 2.18 | 1.57 | 1.36 | 1.47 | -699.00% | 2362.00% | 6111.00% | 24.84% | 0.75 | 39.58% | 0.00% | 0.00% | 17.45% | 9.73 | 5.33 | 2.24 | 1.51 |
| AMPH | Amphastar Pharmaceuticals… | $20.23 | 929.61M | +167% | -56% | -25% | -32% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CRON | Cronos Group Inc. | $2.67 | 1.02B | +1,212% | -39% | -5% | — | — | 0.93 | 5.24 | -12.20 | — | 0.99 | 32.46% | -1.51% | -4.89% | 0.00% | -0.69% | 0.00% | 0.00 | — | 19.59 | 18.88 | 52.68 | -12227.00% | 6440.00% | -9734.00% | 0.01% | 0.55 | 0.06% | 0.00% | — | 0.98% | -62.50 | 1207.50 | 0.95 | 12.80 |
| DVAX | Dynavax Technologies Corp… | $15.50 | 1.82B | +159% | -40% | -64% | -64% | 68.57 | 3.14 | 6.75 | 30.92 | — | 3.15 | 82.17% | -1.49% | 9.85% | 4.48% | -2.66% | 2.75% | 0.43 | -0.61 | 10.80 | 9.67 | 3.47 | -50323.00% | 1936.00% | -3763.00% | 3.21% | 0.85 | 43.90% | 0.00% | 0.00% | 5.34% | -342.86 | 23.49 | 5.10 | 2.81 |
| GDRX | GoodRx Holdings, Inc. | $1.87 | 635.85M | +1,396% | -39% | -10% | +8% | 30.91 | 1.25 | 0.97 | 3.10 | 29.70 | 6.35 | 92.77% | 10.98% | 10.37% | 3.73% | 14.18% | 1.79% | 0.10 | 2.05 | 2.61 | 2.02 | -1.10 | 10407.00% | 57.00% | -3234.00% | 9.94% | 0.55 | 12.45% | 0.00% | 0.00% | 65.21% | 6.53 | 7.43 | 0.72 | 0.29 |
| INVA | Innoviva, Inc. | $22.96 | 1.48B | +363% | -42% | +62% | +354% | 5.67 | 1.31 | 3.62 | 2.57 | 0.69 | 1.58 | 72.33% | 38.52% | 63.78% | 29.09% | 20.10% | 18.47% | 0.00 | 9.81 | 14.64 | 11.79 | -1.44 | 81667.00% | 1852.00% | 392.00% | 12.73% | 3.96 | 28.97% | 0.00% | 0.00% | 45.61% | 6.03 | 5.04 | 2.32 | 3.32 |
| MDXG | MiMedx Group, Inc. | $4.89 | 724.22M | +613% | +792% | -34% | +83% | 14.85 | 2.81 | 1.72 | 6.71 | 103.93 | 3.23 | 82.56% | 15.26% | 11.60% | 21.61% | 45.59% | 16.02% | 0.01 | 35.83 | 4.32 | 3.76 | -1.99 | 1429.00% | 1999.00% | 1311.00% | 10.12% | 1.15 | 71.03% | 0.00% | 0.00% | 12.22% | 8.71 | 7.63 | 1.33 | 7.43 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| PCRX | Pacira BioSciences, Inc. | $21.91 | 942.6M | +137% | -61% | -17% | -68% | 134.83 | 1.37 | 1.31 | 6.38 | — | 3.11 | 71.50% | 2.64% | 3.68% | 0.96% | 2.60% | 0.50% | 0.01 | 1.10 | 4.54 | 2.34 | -1.19 | -10744.00% | 363.00% | -2355.00% | 14.41% | 1.26 | 18.51% | 0.00% | 0.00% | 53.86% | 41.67 | 5.85 | 1.10 | 1.80 |
| PLSE | Pulse Biosciences, Inc. | $18.73 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
- CEO
- Vikram Karnani
- Employees
- 357
- Beta
- 0.64
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($229.65 ÷ $34.32) − 1 = +569.14% (DCF, example).